The Biotinylated Anti-CD48 Antibody (HDLA009) is a valuable tool for researchers studying CD48, a cell surface protein involved in immune responses and cell signaling. This antibody, produced through a biotinylation process, offers high specificity and sensitivity in detecting CD48 in various cell types and tissues. The Biotinylated Anti-CD48 Antibody is ideal for use in applications such as immunohistochemistry, flow cytometry, and immunoprecipitation, providing researchers with a versatile tool for studying CD48 expression and function.
Its biotinylated form allows for easy detection and visualization of CD48 in complex biological samples.CD48 is known to play a role in immune cell activation and regulation, making it a key target in immunology research and studies on autoimmune diseases and cancer. By using the Biotinylated Anti-CD48 Antibody, researchers can gain valuable insights into the role of CD48 in immune responses and potentially develop novel therapeutic strategies targeting this molecule.
Purified from cell culture supernatant by affinity chromatography
Formulation:
Powder
Buffer:
1XPBS
Storage:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Usage:
Research use only
Background:
This gene encodes a member of the CD2 subfamily of immunoglobulin-like receptors which includes SLAM (signaling lymphocyte activation molecules) proteins. The encoded protein is found on the surface of lymphocytes and other immune cells, dendritic cells and endothelial cells, and participates in activation and differentiation pathways in these cells. The encoded protein does not have a transmembrane domain, however, but is held at the cell surface by a GPI anchor via a C-terminal domain which maybe cleaved to yield a soluble form of the receptor. Multiple transcript variants encoding different isoforms have been found for this gene.
